Wedbush Cuts Earnings Estimates for Compass Therapeutics

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities researchers at Wedbush dropped their Q3 2025 earnings per share estimates for shares of Compass Therapeutics in a research report issued to clients and investors on Tuesday, April 1st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.13) per share for the quarter, down from their prior estimate of ($0.10). Wedbush has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.42 EPS.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01).

Several other equities research analysts have also commented on CMPX. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Guggenheim reissued a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $4.00 to $6.00 in a research report on Wednesday. Finally, Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Compass Therapeutics has an average rating of “Buy” and a consensus target price of $11.63.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $1.61 on Friday. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The company has a market cap of $221.94 million, a P/E ratio of -4.34 and a beta of 1.19. The firm has a 50-day moving average of $2.78 and a 200-day moving average of $2.10.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Tower Research Capital LLC TRC lifted its position in shares of Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after acquiring an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new position in Compass Therapeutics in the fourth quarter valued at $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics in the 4th quarter worth about $27,000. Intech Investment Management LLC bought a new position in Compass Therapeutics during the third quarter valued at approximately $30,000. Finally, Mariner LLC purchased a new position in Compass Therapeutics in the 4th quarter worth $30,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.